Session » Infection-related Rheumatic Disease Poster

Date: Saturday, November 7, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 0630

“No Benefit from a Strict Immobilization in Vertebral Osteomyelitis” Vertebral Immobilization and Neurological Complication in Acute Pyogenic Vertebral Osteomyelitis: SPONDIMMO, a Prospective Cohort of 250 Patients

9:00AM-11:00AM: Abstract Number: 0624

Association of Regional Body Composition and Physical Function Using the Short Physical Performance Battery Among Peruvian Women with HIV

9:00AM-11:00AM: Abstract Number: 0644

Characterizations of Cytokine Storm Associated with COVID19

9:00AM-11:00AM: Abstract Number: 0637

Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time

9:00AM-11:00AM: Abstract Number: 0631

Clinical Manifestations and Outcomes in DMARD-Naïve Patients with Chronic Chikungunya Arthritis

9:00AM-11:00AM: Abstract Number: 0641

Cohort of Rheumatic Patients Treated with Rituximab and COVID-19: Does Rituximab Treatment Increases the Severity of SARS-COV2 Infection?

9:00AM-11:00AM: Abstract Number: 0627

Complications of COVID-19 Infection in Patients with Rheumatic Disease: A Case Series

9:00AM-11:00AM: Abstract Number: 0629

COVID-19 Among Patients with Immune-mediated Inflammatory Diseases: A Descriptive Study

9:00AM-11:00AM: Abstract Number: 0640

Covid-19 and Rheumatic and Musculoskeletal Disease Patients: Infection Rates, Attitudes and Medication Adherence

9:00AM-11:00AM: Abstract Number: 0642

COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies

9:00AM-11:00AM: Abstract Number: 0623

Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort

9:00AM-11:00AM: Abstract Number: 0626

Early Rise in CRP Is Associated with Progression to Respiratory Failure and Intubation in COVID-19 Patients

9:00AM-11:00AM: Abstract Number: 0621

Effectiveness of Screening in Patients with Rheumatic Disease Before Commencing Biologic Therapy and Risk of Active Tuberculosis

9:00AM-11:00AM: Abstract Number: 0628

Factors Associated with Knee Osteoarthritis in an Outpatient HIV-1 Clinic over a 26 Year Interval

9:00AM-11:00AM: Abstract Number: 0635

Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0639

Immunological Abnormalities in a SARS-CoV-2-Cytokine Release Syndrome Rheumatology Cohort

9:00AM-11:00AM: Abstract Number: 0622

Infection-induced MPO-ANCA Associated Vasculitis: A Systematic Review of Published Case Reports

9:00AM-11:00AM: Abstract Number: 0634

Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 0625

Machine Learning Model to Predict Culture Positivity in Suspected Septic Arthritis

9:00AM-11:00AM: Abstract Number: 0645

Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis

9:00AM-11:00AM: Abstract Number: 0636

Rheumatology Patient Experience and Trends During the SARS-COV-2 Pandemic

9:00AM-11:00AM: Abstract Number: 0638

Serological Evidence of SARS-CoV-2 in Symptomatic Patients Under Biological Treatment in a Rheumatology Service

9:00AM-11:00AM: Abstract Number: 0632

Systems Approach to Understanding Reasons for Influenza Vaccine Hesitancy in Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 0643

Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection

9:00AM-11:00AM: Abstract Number: 0633

Vitamin D Serum Status in a Cohort of COVID-19 Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].